Bristol-Myers Squibb Company (BMY)
Automate Your Wheel Strategy on BMY
With Tiblio's Option Bot, you can configure your own wheel strategy including BMY - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol BMY
- Rev/Share 23.6129
- Book/Share 9.0671
- PB 6.7672
- Debt/Equity 2.5518
- CurrentRatio 1.2551
- ROIC 0.139
- MktCap 124734014431.0
- FreeCF/Share 6.2935
- PFCF 9.7107
- PE 17.7245
- Debt/Assets 0.5235
- DivYield 0.0407
- ROE 0.3927
- Rating B+
- Score 3
- Recommendation Neutral
- P/E Score 3
- DCF Score 5
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | BMY | Barclays | -- | Overweight | -- | $75 | Feb. 20, 2026 |
| Upgrade | BMY | UBS | Neutral | Buy | -- | $65 | Jan. 7, 2026 |
| Upgrade | BMY | BofA Securities | Neutral | Buy | -- | $61 | Dec. 15, 2025 |
| Upgrade | BMY | Guggenheim | Neutral | Buy | -- | $62 | Dec. 12, 2025 |
| Initiation | BMY | Scotiabank | -- | Sector Perform | -- | $45 | Nov. 13, 2025 |
| Downgrade | BMY | Daiwa Securities | Outperform | Neutral | -- | $42 | Aug. 5, 2025 |
| Initiation | BMY | Cantor Fitzgerald | -- | Neutral | -- | $55 | April 22, 2025 |
| Initiation | BMY | Piper Sandler | -- | Overweight | -- | -- | April 22, 2025 |
| Upgrade | BMY | Jefferies | Hold | Buy | -- | $70 | Dec. 16, 2024 |
| Resumed | BMY | BofA Securities | -- | Neutral | -- | $63 | Dec. 10, 2024 |
News
Bristol Myers Squibb Company (BMY) is Attracting Investor Attention: Here is What You Should Know
Published: February 24, 2026 by: Zacks Investment Research
Sentiment: Positive
Recently, Zacks.com users have been paying close attention to Bristol Myers (BMY). This makes it worthwhile to examine what the stock has in store.
Read More
Bristol Myers Squibb Announces Positive Top-Line Results from Registrational Phase 2 Study of Luspatercept in Adults with Alpha (α)-Thalassemia
Published: February 23, 2026 by: Business Wire
Sentiment: Neutral
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #BMS--Bristol Myers Squibb Announces Positive Top-Line Results from Registrational Phase 2 Study of Luspatercept in Adults with Alpha (α)-Thalassemia.
Read More
Merck vs. Bristol Myers: Which Pharma Stock Is a Better Pick in 2026?
Published: February 20, 2026 by: Zacks Investment Research
Sentiment: Negative
BMY edges past MRK as generic headwinds bite, but new drug launches, cost cuts and a stronger 2026 outlook tilt the investment case in its favor.
Read More
Bristol-Myers Squibb: Oncology Franchise Remains A Core Strength
Published: February 19, 2026 by: Seeking Alpha
Sentiment: Positive
Bristol-Myers Squibb Company ended 2025 and started this year on a high note. On February 6, its stock reached a 52-week high of $63.3. One of the reasons BMY is once again becoming a Wall Street favorite is the 49% year-over-year increase in Breyanzi sales to $392 million in Q4.
Read More
FDA Accepts BMY's NDA for Iberdomide Combo in Multiple Myeloma
Published: February 18, 2026 by: Zacks Investment Research
Sentiment: Positive
FDA accepts and grants priority review to Bristol Myers' NDA for iberdomide combo in relapsed or refractory multiple myeloma. A decision is due on Aug. 17, 2026.
Read More
Can BMY's Growth Portfolio Counter Legacy Drugs Decline in 2026?
Published: February 17, 2026 by: Zacks Investment Research
Sentiment: Negative
BMYs 2025 results highlight a shifting revenue mix as 17% growth in newer drugs offsets legacy declines, with more erosion expected in 2026.
Read More
Bristol Myers Squibb Company (BMY) Is a Trending Stock: Facts to Know Before Betting on It
Published: February 11, 2026 by: Zacks Investment Research
Sentiment: Positive
Zacks.com users have recently been watching Bristol Myers (BMY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Read More
Will BMY's Legacy Portfolio Decline Weigh on Its 2026 Top Line?
Published: February 10, 2026 by: Zacks Investment Research
Sentiment: Negative
BMY's legacy drugs see sharp generic erosion in 2026, but Eliquis growth and guidance shape expectations as competition heats up in oncology.
Read More
BMY Up 7.6% Post Q4 Earnings: Should You Buy, Sell or Hold the Stock?
Published: February 09, 2026 by: Zacks Investment Research
Sentiment: Neutral
BMY jumps after strong Q4 2025 results as its growth portfolio drives beats, lifts sentiment and offsets generic pressure on legacy drugs.
Read More
Dow Tumbles Over 400 Points; Bristol Myers Reports Strong Q4 Results
Published: February 05, 2026 by: Benzinga
Sentiment: Neutral
U.S. stocks traded lower midway through trading, with the Dow Jones index falling more than 400 points on Thursday.
Read More
Weekly Jobless Claims Exceed Expectations
Published: February 05, 2026 by: Zacks Investment Research
Sentiment: Positive
Weekly Jobless Claims Exceed Expectations.
Read More
Bristol-Myers Stock Up as Q4 Earnings and Revenues Beat Estimates
Published: February 05, 2026 by: Zacks Investment Research
Sentiment: Positive
BMY beats Q4 earnings and revenue estimates as its Growth Portfolio jumps 16%, lifting shares despite continued declines in legacy drugs.
Read More
Jobless Claims Pop Up a Bit, Major Morning for Earnings
Published: February 05, 2026 by: Zacks Investment Research
Sentiment: Positive
Jobless Claims notched their highest weekly print since early December, while BMY, RL, COP & more report earnings.
Read More
Bristol Myers Just Crushed Earnings, and the Real Catalyst Hasn't Even Hit Yet
Published: February 05, 2026 by: 24/7 Wall Street
Sentiment: Positive
Bristol Myers Squibb (NYSE:BMY) reported Q4 2025 revenue of $12.5 billion, essentially flat year-over-year, with full-year 2025 revenue reaching $48.2 billion.
Read More
Bristol Myers (BMY) Reports Q4 Earnings: What Key Metrics Have to Say
Published: February 05, 2026 by: Zacks Investment Research
Sentiment: Positive
Although the revenue and EPS for Bristol Myers (BMY) give a sense of how its business performed in the quarter ended December 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Read More
Bristol Myers Squibb (BMY) Tops Q4 Earnings and Revenue Estimates
Published: February 05, 2026 by: Zacks Investment Research
Sentiment: Positive
Bristol Myers Squibb (BMY) came out with quarterly earnings of $1.26 per share, beating the Zacks Consensus Estimate of $1.15 per share. This compares to earnings of $1.67 per share a year ago.
Read More
Will Reblozyl Shine in Bristol Myers' Fourth-Quarter Results?
Published: February 03, 2026 by: Zacks Investment Research
Sentiment: Positive
BMY leans on fast-growing Reblozyl, now a $2B+ franchise, to fuel results as generics pressure legacy drugs ahead of Q4 earnings.
Read More
Bristol Myers Squibb Introduces "Change the Target. Change What's Possible.
Published: February 03, 2026 by: Business Wire
Sentiment: Neutral
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #FXIa--Bristol Myers Squibb Introduces "Change the Target. Change What's Possible.” to Highlight Unmet Needs in Cardiovascular and Thromboembolic Care.
Read More
What's in Store for These 5 Pharma Bigwigs This Earnings Season?
Published: February 02, 2026 by: Zacks Investment Research
Sentiment: Neutral
As earnings season accelerates, pharma heavyweights LLY, MRK, NVO, BMY and PFE prepare to reveal their Q4 results amid a strong sector start.
Read More
Unveiling Bristol Myers (BMY) Q4 Outlook: Wall Street Estimates for Key Metrics
Published: February 02, 2026 by: Zacks Investment Research
Sentiment: Neutral
Evaluate the expected performance of Bristol Myers (BMY) for the quarter ended December 2025, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Read More
Should You Buy, Hold, or Sell BMY Stock Ahead of Q4 Earnings?
Published: February 02, 2026 by: Zacks Investment Research
Sentiment: Positive
BMY heads into Q4 2025 earnings with strong Opdivo momentum, even as generic pressure continues to weigh on legacy drug sales.
Read More
Will BMY's Oncology Collaborations Drive Its Next Growth Phase?
Published: January 30, 2026 by: Zacks Investment Research
Sentiment: Positive
BMY boosts its oncology pipeline with a Janux deal on tumor-activated therapy, alongside encouraging pumitamig data and multiple cancer collaborations.
Read More
Analysts Estimate Bristol Myers Squibb (BMY) to Report a Decline in Earnings: What to Look Out for
Published: January 29, 2026 by: Zacks Investment Research
Sentiment: Negative
Bristol Myers (BMY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Read More
Investors Heavily Search Bristol Myers Squibb Company (BMY): Here is What You Need to Know
Published: January 26, 2026 by: Zacks Investment Research
Sentiment: Positive
Bristol Myers (BMY) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Read More
Bristol-Myers Squibb: Solid Tumor Collaboration With Janux And Camzyos Expansion
Published: January 23, 2026 by: Seeking Alpha
Sentiment: Positive
Bristol-Myers Squibb (BMY) remains a Strong Buy as it accelerates Growth Portfolio revenues and executes strategic oncology expansion. BMY's collaboration with Janux Therapeutics positions it to enter the solid tumor market, leveraging TRACTr technology for long-term oncology growth. Camzyos delivered 89% YoY revenue growth and promising phase 3 SCOUT-HCM results, supporting potential label expansion to adolescent oHCM patients.
Read More
Janux Therapeutics Strikes Bristol Myers Biotech Deal Worth $800 Million
Published: January 22, 2026 by: Benzinga
Sentiment: Positive
Janux Therapeutics, Inc. (NASDAQ: JANX) on Thursday announced a collaboration and exclusive worldwide license agreement with Bristol Myers Squibb Co. (NYSE: BMY).
Read More
Is BMY's Deep Pipeline the Key to Its Next Growth Phase?
Published: January 22, 2026 by: Zacks Investment Research
Sentiment: Positive
BMY spotlights a deep pipeline with multi-billion-dollar potential, key late-stage data readouts ahead, and encouraging uptake of the new schizophrenia drug Cobenfy.
Read More
BMY vs GSK: Which Biopharma Giant Has Better Prospects for Now?
Published: January 20, 2026 by: Zacks Investment Research
Sentiment: Neutral
Bristol Myers Squibb BMY and GSK PLC GSK are among the largest global biopharma companies with broad and diverse portfolios.
Read More
2 Buffett Stocks to Load Up On—And 1 to Ditch
Published: January 19, 2026 by: MarketBeat
Sentiment: Negative
Warren Buffett made some substantial changes to the Berkshire Hathaway Inc. NYSE: BRK.B portfolio in the first quarters of 2025, including selling off some $4 billion in Apple Inc. NASDAQ: AAPL shares in order to amass a major cash and Treasuries reserve.
Read More
Will Positive Data on Camzyos Strengthen BMY's Cardiovascular Portfolio?
Published: January 14, 2026 by: Zacks Investment Research
Sentiment: Positive
BMY reports positive late-stage data for Camzyos in adolescents with oHCM, expanding its cardiovascular outlook amid pipeline setbacks and rising competition.
Read More
About Bristol-Myers Squibb Company (BMY)
- IPO Date 1972-06-01
- Website https://www.bms.com
- Industry Drug Manufacturers - General
- CEO Christopher S. Boerner
- Employees 34100